Literature DB >> 22377150

Characterization of a recurrent poor-quality embryo morphology phenotype and zygote transfer as a rescue strategy.

Nathalie Sermondade1, Vanina Delarouzière, Célia Ravel, Isabelle Berthaut, Lieve Verstraete, Emmanuelle Mathieu, Jean-Marie Antoine, Jacqueline Mandelbaum.   

Abstract

Some patients in IVF programmes repeatedly display an abnormal embryonic development characterized as soon as day 2 post fertilization by a high rate (>60%) of highly fragmented embryos (⩾40% of cytoplasmic fragments) leading to recurrent IVF failures. This study postulated that, for various maternal reasons, some embryos were unable to withstand the in-vitro environment and an early pronucleate-stage transfer was proposed to these couples. Fifty-three patients with recurrent IVF failures (a mean of 2.8±1.0 previous attempts) characterized by low embryonic quality (a mean of 62.7% of the embryos with extended fragmentation) were included this transfer protocol. As in previous cycles, the mean number of oocytes retrieved and the fertilization rate were normal. The mean number of zygotes per transfer was 2.24. Fourteen clinical pregnancies were obtained, representing a pregnancy rate and a delivery rate per oocyte retrieval of 26.4% and 18.9%, respectively. Recurrent heavy and early embryo fragmentation in vitro characterizes around 3% of IVF couples and leads to lack of transfer or implantation failure. These data on fresh zygote transfers are encouraging and may provide a valid alternative solution for some of these patients. Some patients in IVF programmes repeatedly display an abnormal embryonic development characterized as soon as day 2 post fertilization by a high rate of highly fragmented embryos, leading to recurrent IVF failures. We hypothesized that, for various reasons, some embryos were unable to withstand the in-vitro environment and an early pronucleate stage transfer was proposed to these couples. Fifty-three patients with recurrent IVF failures characterized by low embryonic quality were included in this transfer protocol. As in previous cycles, the mean number of oocytes retrieved and the fertilization rate were normal. The mean number of zygotes per transfer was 2.24. Fourteen clinical pregnancies were obtained, representing a pregnancy rate and a delivery rate per oocyte retrieval of 26.4% and 18.9%, respectively. Recurrent early and heavy embryo fragmentation in vitro characterizes around 3% of IVF couples and leads to lack of transfer or implantation failure. Our data on fresh zygote transfers are encouraging and may provide a valid alternative solution for these patients.
Copyright © 2012 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22377150     DOI: 10.1016/j.rbmo.2012.01.004

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  4 in total

1.  Melatonin Improves Quality of Repeated-Poor and Frozen-Thawed Embryos in Human, a Prospective Clinical Trial.

Authors:  Zhongjian Bao; Guangdong Li; Rongxiang Wang; Songguo Xue; Yong Zeng; Shoulong Deng
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-13       Impact factor: 6.055

2.  The importance of the cleavage stage morphology evaluation for blastocyst transfer in patients with good prognosis.

Authors:  Daniela P A F Braga; Amanda S Setti; Rita C S Figueira; Assumpto Iaconelli; Edson Borges
Journal:  J Assist Reprod Genet       Date:  2014-06-04       Impact factor: 3.412

3.  Disposition of embryos from women who only produced morphologically poor embryos on day three.

Authors:  Pin-Yao Lin; Chia-Yun Lin; Ni-Chin Tsai; Fu-Jen Huang; Hsin-Ju Chiang; Yu-Ju Lin; Yu-Ting Su; Kuo-Chung Lan
Journal:  Biomed J       Date:  2021-01-15       Impact factor: 7.892

4.  Rescue Potential of Supportive Embryo Culture Conditions on Bovine Embryos Derived from Metabolically Compromised Oocytes.

Authors:  Anouk Smits; Jo L M R Leroy; Peter E J Bols; Jessie De Bie; Waleed F A Marei
Journal:  Int J Mol Sci       Date:  2020-11-02       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.